[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340661-105":59,"doc-detail-340661-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","enhancing-fc-mediated-effector-functions-of-monoclonal-antibodies-the-example-of-hexabodies","Enhancing Fc-mediated effector functions of monoclonal antibodies: The example of HexaBodies","","Rituximab’s approval in 1997 catalyzed the widespread use of monoclonal antibody therapies across hematological and solid cancers, supported by broad applicability, strong safety, and specific targeting of cancer-associated surface antigens. Antitumor activity is driven by Fc-mediated mechanisms—ADCC, ADCP, and CDC—whose effectiveness has been improved via Fc domain engineering. This review surveys approaches to enhance Fc effector functions, emphasizing HexaBody technology to promote mAb hexamerization on target cells, boosting complement activation and receptor clustering, and summarizing development from preclinical to clinical testing for B-cell malignancies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/enhancing-fc-mediated-effector-functions-of-monoclonal-antibodies-the-example-of-hexabodies/340661/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/enhancing-fc-mediated-effector-functions-of-monoclonal-antibodies-the-example-of-hexabodies/340661.png","ImageObject",300,407,{"name":92,"@type":93},"Theodora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What are Fc-mediated effector functions of monoclonal antibodies discussed in the review?","Question",{"text":112,"@type":113},"They include antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), all mediated via the Fc domain.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does HexaBody technology aim to improve antibody activity?",{"text":117,"@type":113},"It is designed to enhance hexamerization of mAbs on the target cell surface, leading to stronger complement activation, CDC, and receptor clustering.",{"name":119,"@type":110,"acceptedAnswer":120},"What development stages are covered for HexaBodies in the review?",{"text":121,"@type":113},"The review summarizes development and evaluation through preclinical and clinical testing for HexaBodies intended for B-cell malignancies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340661,1790197534,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","DOI: 10. 1111/imr.13394  \nI NV IT E D RE V IE W  \nEnhancing Fc-mediated effector functions of monoclonal antibodies: The example of HexaBodies  \nHilma J. van der Horst | Tuna Mutis   \nDepartment of Hematology, Cancer Center Amsterdam, Amsterdam UMC, VU Medical Center, Amsterdam, The Netherlands  \nCorrespondence  \nHilma J. van der Horst and Tuna Mutis, Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, VU Medical Center, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands.  \nEmail: [h.vanderhorst1@amsterdamumc. nl](h.vanderhorst1@amsterdamumc. nl)and [t. mutis@amsterdamumc. nl](t. mutis@amsterdamumc. nl)  \nPresent address  \nHilma J. van der Horst, Department of Fundamental Oncology, Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland  \nSummary  \nSince the approval of the CD20-targeting monoclonal antibody (mAb) rituximab for the treatment of lymphoma in 1997, mAb therapy has significantly transformed cancer treatment. With over 90 FDA-approved mAbs for the treatment of various hematological and solid cancers, modern cancer treatment relies heavily on these therapies. The overwhelming success of mAbs as cancer therapeutics is attributed to their broad applicability, high safety profile, and precise targeting of cancer-associated surface antigens. Furthermore, mAbs can induce various anti-tumor cytotoxic effector mechanisms including antibody-dependent cellular cytotoxicity (ADCC), antibodydependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), all of which are mediated via their fragment crystallizable (Fc) domain. Over the past decades, these effector mechanisms have been substantially improved through Fc domain engineering. In this review, we will outline the different approaches to enhance Fc effector functions via Fc engineering of mAbs, with a specific emphasis on the so-called “HexaBody” technology, which is designed to enhance the hexamerization of mAbs on the target cell surface, thereby inducing greater complement activation, CDC, and receptor clustering. The review will summarize the development, preclinical, and clinical testing of several HexaBodies designed for the treatment of B-cell malignancies, as well as the potential use of the HexaBody technology beyond Fc-mediated effector functions.  \nK E Y WO R D S  \nantibody therapy, B-cell malignancies, complement-mediated cytotoxicity, Fc-engineering, HexaBody technology, multiple myeloma  \n1 | INTRODUCTION  \nAntibodies (Abs), produced by B cells, are key components of our antigen-specific adaptive immune system.1 While it has long been known that they are crucial for defending our bodies against infections and diseases,2 the idea of using Abs in cancer treatment  \noriginated from observations in the previous century, demonstrating that the immune system could recognize and attack cancer cells by identifying their surface antigens via Abs. 3,4 Since then, extensive research has discovered several cell surface antigens on cancer cells that are either shared with healthy cells or expressed at much higher levels compared to their healthy counterparts, fueling the idea of  \nThis article is part of a series of reviews covering Effector Functions of Antibodies in Health and Disease appearing in Volume 328 of Immunological Reviews.  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2024 The Author(s) . Immunological Reviews published by John Wiley & Sons Ltd.  \ntargeting such cancer-associated surface antigens with antibodies for therapeutic purposes.5  \nThe development of the mouse hybridoma technology in 1975, which enabled large-scale production of mAbs, is generally considered a major step toward the clinical application of murine antibodies.6 However, it soon b","cbCaibhEacstkIFO","https://ap.wps.com/l/cbCaibhEacstkIFO","pdf",826085,"English","# Summary\n# Key Words\n# 1 | Introduction","[{\"question\":\"What are Fc-mediated effector functions of monoclonal antibodies discussed in the review?\",\"answer\":\"They include antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), all mediated via the Fc domain.\"},{\"question\":\"How does HexaBody technology aim to improve antibody activity?\",\"answer\":\"It is designed to enhance hexamerization of mAbs on the target cell surface, leading to stronger complement activation, CDC, and receptor clustering.\"},{\"question\":\"What development stages are covered for HexaBodies in the review?\",\"answer\":\"The review summarizes development and evaluation through preclinical and clinical testing for HexaBodies intended for B-cell malignancies.\"}]","Enhancing Fc-mediated effector functions of monoclonal antibodies: The example of HexaBodies | PDF",1790037978,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ed29522601017081e5917cf655a7addf.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eca825cf197ac35f99e7410f84dd8939.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e92dad166c058df069feee31d0f2a8d.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bad131d92d56900106d3e25f19b5b75f.webp",980,1287]